Thermo Fisher Scientific Inc (NYSE:TMO) Shares Sold by Boston Financial Mangement LLC

Boston Financial Mangement LLC reduced its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 6.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,747 shares of the medical research company’s stock after selling 1,226 shares during the period. Boston Financial Mangement LLC’s holdings in Thermo Fisher Scientific were worth $2,880,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. Wellington Management Group LLP raised its position in shares of Thermo Fisher Scientific by 5.6% in the first quarter. Wellington Management Group LLP now owns 7,512,152 shares of the medical research company’s stock worth $1,153,867,000 after buying an additional 398,622 shares during the period. Pictet Asset Management Ltd. raised its position in shares of Thermo Fisher Scientific by 1.2% in the first quarter. Pictet Asset Management Ltd. now owns 2,407,464 shares of the medical research company’s stock worth $369,786,000 after buying an additional 29,513 shares during the last quarter. Pioneer Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 1.6% in the first quarter. Pioneer Investment Management Inc. now owns 2,219,085 shares of the medical research company’s stock worth $340,851,000 after buying an additional 34,012 shares during the last quarter. Findlay Park Partners LLP raised its position in shares of Thermo Fisher Scientific by 20.8% in the first quarter. Findlay Park Partners LLP now owns 2,032,151 shares of the medical research company’s stock worth $312,138,000 after buying an additional 350,000 shares during the last quarter. Finally, C WorldWide Group Holding A S raised its position in shares of Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after buying an additional 1,772,300 shares during the last quarter. 87.15% of the stock is owned by institutional investors and hedge funds.

Shares of Thermo Fisher Scientific Inc (TMO) traded down 0.42% during midday trading on Wednesday, hitting $173.26. The stock had a trading volume of 4,284,555 shares. The company’s 50 day moving average price is $176.88 and its 200-day moving average price is $164.14. The firm has a market capitalization of $67.57 billion, a PE ratio of 30.18 and a beta of 1.06. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.03 EPS. Equities analysts predict that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s payout ratio is 10.45%.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/08/09/boston-financial-mangement-llc-lowers-position-in-thermo-fisher-scientific-inc-nysetmo-updated.html.

A number of equities analysts have issued reports on the company. Bank of America Corporation increased their price target on Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Jefferies Group LLC increased their target price on Thermo Fisher Scientific from $160.00 to $175.00 and gave the company a “hold” rating in a report on Friday, April 28th. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Citigroup Inc. restated a “buy” rating and issued a $201.00 target price (up previously from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. One equities research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $188.56.

In other news, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total value of $3,455,800.00. Following the completion of the sale, the chief executive officer now directly owns 269,279 shares in the company, valued at approximately $46,528,718.41. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,188 shares of company stock valued at $4,702,223. Company insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply